JP2025507971A5 - - Google Patents

Info

Publication number
JP2025507971A5
JP2025507971A5 JP2024552478A JP2024552478A JP2025507971A5 JP 2025507971 A5 JP2025507971 A5 JP 2025507971A5 JP 2024552478 A JP2024552478 A JP 2024552478A JP 2024552478 A JP2024552478 A JP 2024552478A JP 2025507971 A5 JP2025507971 A5 JP 2025507971A5
Authority
JP
Japan
Application number
JP2024552478A
Other languages
Japanese (ja)
Other versions
JP2025507971A (ja
JPWO2023164775A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2023/050280 external-priority patent/WO2023164775A1/en
Publication of JP2025507971A publication Critical patent/JP2025507971A/ja
Publication of JP2025507971A5 publication Critical patent/JP2025507971A5/ja
Publication of JPWO2023164775A5 publication Critical patent/JPWO2023164775A5/ja
Pending legal-status Critical Current

Links

JP2024552478A 2022-03-04 2023-03-03 前立腺特異的膜抗原を標的とする放射性標識化合物 Pending JP2025507971A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316595P 2022-03-04 2022-03-04
US63/316,595 2022-03-04
PCT/CA2023/050280 WO2023164775A1 (en) 2022-03-04 2023-03-03 Radiolabeled compounds targetng the prostate-specific membrane antigen

Publications (3)

Publication Number Publication Date
JP2025507971A JP2025507971A (ja) 2025-03-21
JP2025507971A5 true JP2025507971A5 (https=) 2026-03-10
JPWO2023164775A5 JPWO2023164775A5 (https=) 2026-03-10

Family

ID=87882764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552478A Pending JP2025507971A (ja) 2022-03-04 2023-03-03 前立腺特異的膜抗原を標的とする放射性標識化合物

Country Status (6)

Country Link
US (1) US20250186627A1 (https=)
EP (1) EP4486756A1 (https=)
JP (1) JP2025507971A (https=)
AU (1) AU2023226956A1 (https=)
CA (1) CA3244865A1 (https=)
WO (1) WO2023164775A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210909A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
WO2025055943A1 (en) * 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
CN121773094A (zh) * 2023-09-12 2026-03-31 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3544960A1 (en) * 2016-11-23 2019-10-02 Cancer Targeted Technology LLC Albumin-binding psma inhibitors
US11629201B2 (en) * 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof
CN114401947B (zh) * 2019-06-21 2024-11-29 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物
US11850291B2 (en) * 2019-10-25 2023-12-26 National Atomic Research Institute PSMA targeted radiotherapy medicine and preparation method thereof

Similar Documents

Publication Publication Date Title
JP2025507971A5 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BY23965C1 (https=)
CN307045229S (https=)
BY13140U (https=)
CN307049862S (https=)
CN307049431S (https=)
CN307049262S (https=)
CN307047659S (https=)
CN307046589S (https=)
CN307046140S (https=)
CN307046055S (https=)
CN307045948S (https=)
CN307045549S (https=)
CN307045492S (https=)
CN307045334S (https=)
CN307044972S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)